---
title: "IBEX Holdings Q3 2026 earnings preview"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285273264.md"
description: "IBEX Holdings is set to announce its Q3 earnings on May 6th, with a consensus EPS estimate of $0.85, reflecting a 3.7% year-over-year increase, and a revenue estimate of $155.86 million, up 10.8% year-over-year. The company has a strong track record, having beaten EPS and revenue estimates 88% of the time over the past two years."
datetime: "2026-05-05T21:45:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285273264.md)
  - [en](https://longbridge.com/en/news/285273264.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285273264.md)
generator: "portal-rs"
---

# IBEX Holdings Q3 2026 earnings preview

IBEX Holdings (IBEX) is scheduled to announce Q3 earnings results on Wednesday, May 6th, after market close. The consensus EPS Estimate is $0.85 (+3.7% Y/Y) and the consensus Revenue Estimate is $155.86M (+10.8% Y/Y). Over the last 2 years, IBEX has beaten EPS estimates 88% of the time and has beaten revenue estimates 88% of the time. Over the last...

### Related Stocks

- [IBEX.US](https://longbridge.com/en/quote/IBEX.US.md)
- [SRVR.US](https://longbridge.com/en/quote/SRVR.US.md)
- [DTCR.US](https://longbridge.com/en/quote/DTCR.US.md)
- [IDGT.US](https://longbridge.com/en/quote/IDGT.US.md)

## Related News & Research

- [Ibex CEO meets Honduras President Asfura on BPO investment opportunities](https://longbridge.com/en/news/295410811.md)
- [Pepco buys back 36,462,201 shares for EUR 400 million in tender offer at PLN 47.52 each](https://longbridge.com/en/news/295888180.md)
- [XORTX Therapeutics Inc. GAAP EPS of -$1.05](https://longbridge.com/en/news/296650983.md)
- [Intelligent Bio Solutions GAAP EPS of -$8.44, revenue of $4.22M](https://longbridge.com/en/news/296440057.md)
- [Twin Disc GAAP EPS of $0.64 beats by $0.41, revenue of $114.4M beats by $14.05M](https://longbridge.com/en/news/296489215.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**